Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome

Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome

INTRODUCTION[|]The purpose of this study is to report our functional and anatomical results of intravitreal ranibizumab (IVR) for choroidal neovascularization secondary to pathological myopia (mCNV).[¤]METHODS[|]In this retrospective study, 32 mCNV patients' 32 eyes were evaluated. After one IV...

Full description

Bibliographic Details
Main Authors: İrfan Perente, Özgür Artunay, Alper Şengül
Format: Article
Language:English
Published: KARE Publishing 2018-04-01
Series:Beyoglu Eye Journal
Subjects:
central macular thickness
intravitreal ranibizumab
myopic choroidal neovascularization.
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-88598

Similar Items

Similar Items